

No English title available

Patent Number: FR2752732

Publication date: 1998-03-06

Inventor(s): BOUGARET JOEL;; GOUTAY ERIC;; AVAN JEAN LOUIS;; PAILLARD BRUNO

Applicant(s): PF MEDICAMENT (FR)

Requested

Patent:  [FR2752732](#)

Application

Number: FR19960010528 19960828

Priority Number

(s): FR19960010528 19960828




IPC

Classification: A61K9/52; C07C233/57

EC

Classification: [A61K9/16K2](#), [A61K9/16H6F](#), [A61K9/50H6F2B](#), [A61K9/50K2](#), [A61K31/165](#)

Equivalents:

AU4121297,  [AU727018](#), BR9711378, CN1232387, DE69710757D,  [EP0939626](#)
(WO9808495), [B1](#), ES2171991T, JP2000516946T, PT939626T,  [WO9808495](#)

Abstract

The invention concerns a galenic formula with prolonged release, for oral administration of a single daily dose of 60 to 140 mg of Milnacipran, having a multi-particulate form containing a plurality of microgranules each comprising an active microsphere containing a saccharose and/or starch nucleus of a size grade between 200 and 2000 μ m and containing 150 to 1000 μ m of Milnacipran and a binding agent, each microgranule being coated with a film, with a base of at least one polymer insoluble in water but permeable to physiological liquids, of a thickness between 20 and 100 μ m, the said galenic formula enabling an in vitro release corresponding to the following pattern: between 10 and 55 % of the dose released in 2 hours, between 40 and 75 % of the dose released in 4 hours, between 70 and 90 % of the dose released in 8 hours, between 80 and 100 % of the dose released in 12 hours.

Data supplied from the esp@cenet database - I2